Chronic Ocular Surface Pain Market Size & Share, by Route of Administration (Topical, Oral, Injectable); Indication; Treatment Type - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

Growth Drivers

• Rising prevalence of dry eyes: The chronic ocular surface pain market is characterized by dry eye disease, other forms of surface disorder, or the presence of a neuropathic pain mechanism. For instance, in January 2023, according to the data unveiled by the National Library of Medicine, the prevalence of Dry Eye Disease (DED) varied between 5% and 50% worldwide. Additionally, postmenopausal women have been more likely to have the condition. Throughout the forecast period, this trend will raise the demand for therapeutic measures and support the expansion of the global market.
  
  In addition to this, as people age, the prevalence of this chronic condition changes. Nonetheless, the prevalence is rising among both the younger and older populations as a result of increased screen time, poor diet, contact lens use, and LASIK procedures. For instance, in April 2023, around 36-75% suffer from dry eyes post-LASIK. As it affects a significant portion of the population, dry eye syndrome has one of the highest overall burdens in terms of healthcare services and costs.
   
• Personalized medication approaches: A pivotal growth driver in the chronic ocular surface pain market is reflected by the shift towards treatment strategies based on the individual needs of patients. For instance, in May 2024, Johnson & Johnson announced two oral research presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle. This included a real-world analysis of the economic value of early genetic testing in patients with inherited retinal diseases and evaluating the role of automatic deep-learning-based algorithms in measuring precursors of geographic atrophy (GA).
  
  Furthermore, an individualized approach not only strengthens the effectiveness of treatment but also reduces side effects, thereby supporting improved compliance and adherence by the patient. For instance, in April 2022, Sandoz revealed the US launch of its generic combination eyedrop brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5%. This is intended to help patients with ocular hypertension (high eye pressure) lower their eye pressure. Consequently, as the market for precision medicine is growing, the chronic ocular surface pain market is expected to boom considerably with innovations aimed toward optimal clinical outcomes.

Challenges

• Underappreciation of eye health monitoring:  The general public's perception of eye health is one of the key factors preventing the chronic ocular surface pain market from expanding. Except in cases of severe symptoms, people do not regularly visit ophthalmologists. Redness, burning, and other symptoms of dry eyes are frequently disregarded and go undiagnosed. For instance, an estimated 5 million people in the UK have never had an eye test, according to a survey released in March 2022 by the Broadgreen University Hospital NHS Trust.
  
  In addition, according to the data published in National Eye Health Week, in September 2024, the population estimated using the total UK population aged 18+ is 56.3 million. 36% have not had an eye test in the last two years, and 4% can’t remember the last time they had an eye test. As a result, fewer patients are eligible to receive treatment with these prescription medications. As a result, the market's potential for growth is constrained and the adoption rate of these eye care products declines.
   
• Healthcare access barrier: The most significant challenge in the chronic ocular surface pain market is the prohibition of proper management of chronic ocular surface pain. As a result, fewer patients are eligible to receive treatment with these prescription medications. As a result, the market's potential for growth is constrained and the adoption rate of these eye care products declines. Patients often face obstacles such as inadequate availability of specialized care, high treatment costs, and limited insurance coverage for advanced therapies.
  
  These factors contribute to delays in diagnosis and treatment, exacerbating patient suffering and diminishing quality of life. These barriers are therefore important in ensuring that there is an improvement in patient outcomes as well as fair access to appropriate interventions in ocular health.